Clinical Trial Update: Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use [Phase 3]

View source ↗

Summary

A Phase 3 open-label safety study of 0.03% DSC127 topical gel for diabetic foot ulcers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcer

Drugs mentioned

• DSC127 Topical Gel (DSC127)

Snippet

Sponsor: Integra LifeSciences Corporation | Conditions: Diabetic Foot Ulcer | Phase 3 | Status: TERMINATED